De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis.

Trial Profile

De-escalation After Natalizumab Treatment With Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2014

At a glance

  • Drugs Interferon beta-1b (Primary) ; Natalizumab
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Oct 2011 Interim results presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 04 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Jun 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top